EPIX Pharmaceuticals, Inc. has announced that the New Drug Application for its novel blood pool MR angiography agent, Vasovist was resubmitted to the US FDA on June 30, 2008.

EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that the New Drug Application (NDA) for its novel blood pool magnetic resonance angiography (MRA) agent, Vasovist (gadofosveset trisodium) was resubmitted to the US Food and Drug Administration (FDA) on June 30, 2008.

If approved, Vasovist will be the first contrast agent approved for marketing in the United States for use with MRA, a non-invasive modality for imaging blood vessels. In 2007, there were approximately 1.3 million MRA procedures performed in the United States using contrast agents.

We look forward to continuing to work with the FDA to bring Vasovist to market in the United States, said Michael G. Kauffman, MD, PhD, chief executive officer of EPIX. Throughout the appeal process for Vasovist, we worked closely with the FDA and the resubmission is a culmination of the work done by our team at EPIX. We remain hopeful that we will achieve approval for Vasovist by the end of 2008 and are focused on executing our strategy to monetize our interest in this valuable asset.

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed